ASCO 2020：11项中国研究被选为口头报告，17项Poster报告

受全球另行冠流感受到影响，原定于5同月29日~6同月2日在芝加哥主办的另行泽西州临床学会（ASCO）年会本年将首次以线上形式主办，这是目前最大规模的线上大型活动。今日，全体会议的简述作文公布，共五103个sessions，华南地区共五有11项分析入围口头报告，17项入围Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

苯甲酸替尼或拉帕替尼加卡培他浜用于HER2+移到病态乳腺胰脏（PHOEBE）：一项III期随机试验里面。

艺术节：移到病态乳腺胰脏

所写：华南地区医学科学院疗养院徐兵河博士、马飞博士，浙江大学另有疗养院胡夕春博士等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态乳腺胰脏国际标准放射治疗后卡培他浜维持人声肌肉注射的III期试验里面（SYSUCC-001）。

艺术节：乳腺胰脏—暂时病态/范围/辅助放射治疗

所写：里面山大学防治其里面心王时树森博士等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移到病态脑的表型相似病态来数据分析脑脊液里面周而复始DNA扫描的概率: 另行工具对抗老获胜

艺术节：另行工具妥善解决老问题

所写：李美芹 李德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对奈及利亚拉非尼作为后半期肝细胞核胰脏的一线放射治疗：一项免费表单、随机、多其里面心II/III期试验里面。

艺术节：消化道胰脏—胃输尿管、癌变和自是

所写：四川大学伊万基夫齐疗养院毕锋博士、华南地区暴政解放军南开疗养院秦叔逵博士等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

华南地区后半期肝胰脏患儿阿帕替尼主干线放射治疗：一项随机、安慰剂印证、双盲III期分析

艺术节：消化道胰脏—胃输尿管、癌变和自是

所写：华南地区暴政解放军南开疗养院秦叔逵博士、四川大学伊万基夫齐疗养院李秋博士等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期住院病态卵巢胰脏二次细胞核减灭术的一项随机III期试验里面：SOC1 / SGOG-OV2。

回顾：内科胰脏症

所写：浙江大学另有里面山疗养院臧荣余博士等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治病态子宫切除术后辅助放射治疗里面的序贯放肌肉注射对比另行放射治疗或启动时放肌肉注射（STARS分析）：一项随机、印证、免费表单的III期试验里面。

全体会议：内科胰脏症

所写：里面山大学防治其里面心凌云博士、刘继红博士等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比肌肉注射用于可切除的EGFR病态状的N1-N2期NSCLC-随机III期临床试验里面的再度相比较生存环境深入分析。

回顾：胰脏症—非小细胞核暂时病态-范围/小细胞核/其他腰部

所写：广东省暴政疗养院吴一龙博士等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR病态状寡移到非小细胞核胰脏症患儿一线过氧化物趋化因子胺建立联系或不建立联系积极前线暂时病态放射治疗：III期免费表单临床随机试验里面（SINDAS）的里面期结果（NCT02893332）。

回顾：胰脏症-非小细胞核移到

所写：贵州省暴政疗养院曾铭博士等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态被害-1（PD-1）的人源化IgG4单克隆抗体建立联系阿昔替尼用于移到病态皮肤阿兹海默患儿的Ib期分析的总生存环境期和生物圣万深入分析。

回顾：阿兹海默/皮肤胰脏

所写：北京师范大学疗养院郭军、盛锡楠博士等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容病态和结果：通用CAR-T细胞核首次人体试验里面放射治疗住院/难治病态T细胞核急病态抗原核白血病（r/r T-ALL）的相容病态和。全体会议：共五同开发里面的放射治疗新技术-免疫放射治疗。所写：王时欣欣等简述：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利嘌呤在后半期输尿管楔形细胞核胰脏患儿里面的应用：一项随机的免费表单II期试验里面（ORIENT-2）。全体会议：消化道胰脏-胃输尿管胰脏、癌变胰脏和自是道胰脏所写：徐建明博士等简述：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异病态CAR-T细胞核对肾母细胞核瘤的根治病态放射治疗全体会议：里面枢神经系统所写：代红久、孙斌、杨东、徐晖、朱美美、魏佳、赵旭东简述：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复有缺陷患儿里面的应用全体会议：共五同开发里面的放射治疗学-免疫放射治疗所写：沈琳博士等简述：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 骨肾CD7-CART放射治疗住院/难治病态ACUTE抗原核白血病/白血病的首开人体临床试验里面全体会议: 共五同开发病态放射治疗学-免疫放射治疗所写简介：张明志，杨林等简述：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度咪唑（T）建立联系应用于后半期实体瘤患儿的Ib期分析全体会议：发展病态放射治疗学--分子特异病态药物和生物学所写：龚继芳，沈琳博士等简述：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin建立联系紫杉醇和nedaplatin放射治疗住院病态或移到病态输尿管楔形细胞核胰脏（ESCC）患儿的II期分析。全体会议：消化道胰脏-胃输尿管、癌变和自是道胰脏的分析所写：王时志强，李玉红，王时德申，王时凤华，任超，谭琼 王时志强、李玉红、王时德深、王时凤华、任超、谭琼简述：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体会议：消化道胰脏-胃输尿管胰脏、癌变胰脏和自是管胰脏的主干线放射治疗所写：宋艳等简述：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体的环RNA分类器用于初始活检时扫描高等级胰脏的分泌物外体的环RNA分类器：一项多其里面心的回顾病态分析全体会议：周而复始系统生殖系统胰脏症---胰脏、睾丸胰脏和胰脏所写简介：Liaoyuan Li等简述：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时病态后半期宫颈胰脏模版肌肉注射后的辅助肌肉注射全体会议: 内科胰脏症所写简介： 李珉珉等简述：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗甲状腺肾病态胰脏的相关病态：基于ALTER01031试验里面的深入分析。会话：多毛所写：沈阳市疗养院正派博士简述：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和平均年龄对安洛替尼放射治疗后患儿故事情节的受到影响: ALTER01031的亚组深入分析全体会议：多毛所写：沈阳市疗养院正派博士简述：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入分析数据分析I-IIIA期非小细胞核胰脏症（NSCLC）患儿术后住院: GASTO1035和GASTO1018的结果全体会议：胰脏症-非小细胞核暂时病态-范围病态/小细胞核/小细胞核/其他胸科胰脏症所写：Si-Yu Wang等简述：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞核胰脏症（NSCLC）里面EGFR过氧化物趋化因子胺的另行型细菌病态的系统全体会议:胰脏症-非小细胞核移到病态胰脏症所写简介：赵昕，金玲玲，满宇，欧青楼，凯氏，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧青楼、凯氏、薛武、杨绍、范敏简述：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验里面里面后半期阿兹海默总生存环境的替代终点全体会议：阿兹海默/皮肤胰脏所写：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简述：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗住院或移到病态原发病态恶病态骨患儿的II期分析全体会议： 遗传病态所写：唐丽娜，牛晓辉，王时震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王时振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后半期遗传病态患儿多线放射治疗里面的相容病态和。全体会议：遗传病态所写：姚伟涛，王时家强，王永，王时欣，杜另行辉，田志浩，牛晓颖 姚伟涛、王时家强、王永、王时鑫、杜鑫辉、田志超、牛晓英简述：11526宣传品：414